Company executive sells 12,000 shares of $MEDP

The Chief Financial Officer and Treasurer of $MEDP took a significant step by selling 12,000 shares of the company on July 24, 2025. This transaction, valued at approximately $5,450,760, represents a disposal of around 66.7% of their shares of this particular class of stock. Following this sale, their ownership now amounts to 6,000 shares in this category of $MEDP stock.

Over the past 6 months, $MEDP insiders have engaged in open market trading of $MEDP stock 4 times. Among these trades, acquisitions were made only once, while the remaining three transactions involved sales. The breakdown of recent insider trading activity for $MEDP shares includes the sale of 12,000 shares by Kevin M. Brady, the CFO & Treasurer, totaling an estimated $5,450,760, the sale of 4,003 shares by Brian T Carley amounting to approximately $1,383,396, the disposal of 1,712 shares by Fred B Jr Davenport for an estimated $516,715, and the purchase of 2 shares by Stephen P Ewald, the General Counsel & Corporate Secretary, valued at $652.

Regarding hedge fund activity related to $MEDP stock, 277 institutional investors have added shares to their portfolios, while 283 have decreased their positions in the most recent quarter. Noteworthy alterations in hedge fund positions include Mawer Investment Management Ltd. adding 696,219 shares to their portfolio in Q1 2025, Capital World Investors reducing their holdings by 434,736 shares in the same period, and Vulcan Value Partners, LLC increasing their stake by 224,578 shares. Other notable moves were seen from Goldman Sachs Group Inc, Camber Capital Management LP, Kensico Capital Management Corp, and Proficio Capital Partners LLC.

Wall Street analysts have been active in assessing $MEDP, issuing buy ratings from 1 firm and sell ratings from another. Notable recent reports include an “Outperform” rating by Mizuho on July 25, 2025, and a “Sell” rating by TD Cowen on July 23, 2025. Multiple analysts have also provided price targets for $MEDP in the last 6 months, with a median target of $436.0. Some of the recent price targets set by analysts include $510.0 by Ann Hynes of Mizuho, $490.0 by Eric Coldwell from Baird, and $430.0 by Justin Bowers from Deutsche Bank.

It is important to note that this article does not constitute financial advice and readers are advised to refer to Quiver Quantitative’s disclaimers for further information on this matter.